Envisagenics

Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence.

Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.

Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.

Envisagenics headquartered in New York, United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Therapeutics, Bioinformatics sector. The company focuses on Biotechnology and has secured $14.6B in funding across 280 round(s). With a team of 11-50 employees, Envisagenics is actively contributing to advancements in Biotechnology. Their latest funding round, Pre Seed Round - Envisagenics, raised $50.0K. Discover more about their projects, partnerships, and impact on our platform.